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Established Facts
• Pathogenic inactivating variants in TSC1 or TSC2 are identified in 85% of the patients with tuberous
sclerosis complex (TSC) using conventional sequencing methods.
• Mosaicism accounts for some cases of TSC where a germline mutation is not found.
• Tumours in TSC typically occur when there is a germline mutation in one allele followed by a “second
hit” with somatic mutation in the other allele.
• Pre-implantation genetic diagnosis offers couples the opportunity to prevent transmission of genetic
disease.

Novel Insights
• Detection of a mosaic variant in select tissues may not represent the primary pathological mutation if
there are systemic manifestations.
• Caution is advised for pre-implantation genetic diagnosis in patients with mosaicism and limited tissue mutation expression.
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Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder that displays a wide spectrum of clinical manifesta-
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tions, often affecting multiple organs including the kidneys,
brain, lungs, and skin. A pathogenic mutation in either the
TSC1 or TSC2 gene can be detected in almost 85% of the cases, with mosaicism accounting for about half of the remaining cases. We report a case of TSC diagnosed clinically, requesting genetic counselling regarding reproductive risks.
No mutation was identified on initial testing of peripheral
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blood; however, mosaicism for a likely pathogenic frameshift variant in TSC2 was detected at a level of 15% in renal
angiomyolipoma tissue. Despite widespread clinical manifestations of TCS, this variant was not detected in skin fibroblasts or saliva, raising the possibility this is an isolated somatic mutation in renal tissue with the underlying germline
mutation not yet identified. This case highlights the difficulties when counselling patients with mosaicism regarding
their reproductive risks and prenatal diagnostic options.
© 2021 S. Karger AG, Basel

Introduction

Tuberous sclerosis complex (TSC) is a complex autosomal dominant disorder characterized by growth of
hamartomas in multiple organ systems [Northrup and
Krueger, 2013]. It has an incidence of 1 in 6,000 live births
and is associated with heterozygous pathogenic mutations involving either the TSC1 or TSC2 tumour suppressor genes, encoding hamartin and tuberin, respectively.
About two-thirds of all cases are de novo, while one-third
of the cases are inherited [Northrup et al., 1999].
Case Report
A 25-year-old female presented to the Genetics Clinic requesting information on prenatal diagnostic options related to tuberous
sclerosis. She initially came to medical attention for right flank
pain. Abdominal ultrasound and computed tomography (CT)
scan showed bilateral renal angiomyolipomas (AMLs) (Fig. 1a, b),
measuring 0.8 × 1.4 cm on the right and 7.8 × 7 × 13 cm on the left.
There was no history of seizures or other neurological abnormalities other than migraine headaches. Cognitive function was excellent. There were no cardiac, pulmonary or visual complaints. Family history was negative for any relatives with TSC. A maternal aunt
and one of her sons had learning disabilities, and another son died
of a congenital heart defect.
Clinical examination revealed angiofibromas on both sides of
her nose, and a fibrous cephalic plaque on the forehead, but no
hypomelanotic macules, ungual fibromas, or shagreen patch.
Enamel pits were found on dental exam.
Further screening demonstrated small retinal hamartomas in
the right eye, multiple cortical tubers in the superior frontal gyrus,
left occipital lobe, right fusiform gyrus and right upper Sylvian fissure, and a subependymal nodule (Fig. 1c, d). No lymphangioleiomyomatosis (LAM), cardiac rhabdomyomas, subependymal giant
cell astrocytomas, or bony lesions were found. In total, she exhibited 5 major criteria and 1 minor criteria, satisfying the diagnostic
criteria of 2 or more major findings for a clinical diagnosis of TSC
[Verhoef et al., 1999; Northrup and Krueger, 2013].
The patient was started on sirolimus to slow the rate of growth
of the AMLs, but she developed worsening migraine headaches
and frequent skin rashes, which resolved in discontinuation of this
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treatment. She was subsequently started on everolimus, which was
better tolerated, but AML growth continued, necessitating embolization of the largest renal AML. However, at follow-up 9 months
later, the AML still measured 6.5 × 5.8 × 11.5 cm. A left robot assisted partial nephrectomy was performed approximately 1 year
after initial presentation, at which time biopsies of affected renal
tissue and overlying skin were obtained for DNA testing.
Molecular and Cytogenetic Investigations
Testing of DNA from peripheral blood was performed on 2 occasions using a combination of next-generation sequencing (NGS)
and Sanger sequencing to cover the full coding regions of both
TSC1 (NM_000368.4) and TSC2 (NM_000548.3). This included
analysis of intronic regions within 20 bases of flanking each exon.
This testing was performed through a commercially available panel at Prevention Genetics (www.preventiongenetics.com), and no
pathogenic or likely pathogenic variants were found in DNA from
peripheral blood.
MLPA was also performed using a multiplex PCR-based reaction. This individual was negative for deletions and duplications
within the genomic region encompassing the TSC1 (NM_000368.4)
and TSC2 (NM_000548.3) genomic regions. At the time, MLPA
probe mixes used included: (1) P124-TSC1, which had full gene
coverage of 1 probe per exon (exons 1–23), and (2) P046-TSC2,
which had full gene coverage of1 probe per exon (exons TSC-upstream-41, now known as exons 1–42).
Karyotyping was performed on peripheral blood to investigate
for a translocation involving TSC1 or TSC2, with normal results. Microarray analysis was performed using the Affymetrix CytoScan HD
microarray. Genomic linear positions were given relative to NCBI
genome build 37 (hg19), while analysis was performed using Chromosome Analysis Suite (ChAS; Affymetrix, version NA32.3). Chromosome microarray testing also yielded no CNVs involving TSC1 or
TSC2. Therefore, this patient was initially classified as TSC with no
pathogenic variant identified. NGS on AML tumour tissue obtained
at time of partial nephrectomy showed heterozygosity for a likely
pathogenic variant (American College of Medical Genetics (ACMG)
classification category 4) in NM_000548.3(TSC2):c.2046dup
(p.Ser683Valfs*20) with mosaicism at a level of ∼15%. The minimum acceptable coverage for all reported genomic regions by NGS
was >25×. There were no regions reported with <25× read depth. In
addition, as per Prevention Genetics protocol, any regions with insufficient coverage by NGS were covered by Sanger sequencing.
NGS on cultured fibroblasts obtained from a skin biopsy of the
abdomen at the site of nephrectomy surgical incision yielded negative results for the c.2046dupG variant. A sample of DNA from
saliva also did not reveal the variant.

Discussion

The TSC2 c.2046dupG variant found in this patient’s
AML results in a frameshift and premature truncation of
the protein (p.Ser683Valfs*20) which has not previously
been described in the TSC Variation Databases (http://
chromium.lovd.nl/LOVD2/TSC/home.php). The variant is predicted to be pathogenic, since the majority of
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Fig. 1. Computed tomography imaging of
abdomen and brain. a Axial image on CT
abdomen – arrow indicates position of the
right angiomyolipoma. b Coronal image
on CT abdomen – arrow indicates position
of the left angiomyolipoma. c CT brain –
arrow indicates a cortical tuber in the superior frontal gyrus. d CT brain – arrow indicates a cortical tuber in the left occipital
lobe.
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TSC mutations are inactivating. Our patient did not have
the TSC2: c.2046dupG variant or any other variant identified in skin, blood or saliva, despite the widespread clinical manifestations of TSC affecting brain (hamartomas),
skin (angiofibromas and forehead plaque), eyes (retinal
hamartomas), kidneys (AMLs), and teeth (enamel pits).
In patients with a clinical diagnosis of TSC, conventional genetic testing detects a mutation in about 85% of
the cases, with one-third involving TSC1 and two-thirds
involving TCS2. Of those with no mutation identified,
NGS detects mosaicism for mutations in blood, saliva, or
AML in about half [Verhoef et al., 1999]. Five to ten percent of the cases carry a variant of uncertain significance
or remain with no mutation identified [Peron et al., 2018].
In mosaic cases, skin biopsies tend to have a higher mutation detection rate than either saliva or blood, often with
a higher mutant allele frequency compared to saliva or
blood [Tyburczy et al., 2015a].
Crino et al. [2010] showed that 15 out of 16 individuals
with germline TSC1 or TSC2 mutations had a somatic
156

Mol Syndromol 2021;12:154–158
DOI: 10.1159/000513326

mutation in cortical tubers, supporting Knudson’s 2-hit
hypothesis of tumour development due to biallelic gene
inactivation [Crino et al., 2010]. A study of facial angiofibromas demonstrated a TSC1 or TSC2 mutation, either
germline or mosaic, in 82% of the patients, with a second
hit demonstrated in half of these cases [Tyburczy et al.,
2014]. In patients with germline TSC2 mutations and
multifocal renal cell carcinomas, multiple independent
second hit point mutations or loss of heterozygosity have
been identified in the renal tumours [Tyburczy et al.,
2015b]. The combination of pulmonary LAM with renal
AML constitutes 1major criterion for the diagnosis of
TSC, and may also occur sporadically [Carsillo et al.,
2000]. Patients with TSC-associated LAM usually have
1TSC2 germline mutation and 1acquired mutation in the
affected tissues, while those with sporadic LAM have 2somatic mutations [Smolarek et al., 1998; Carsillo et al.,
2000]. Thus, in patients with germline TSC mutations,
the finding of mosaicism for a different TSC variant in a
TSC-related tumour usually constitutes the second hit.
Ikeda/House/Connaughton/Pautler/Siu/
Jones

There are 2 possible interpretations of the molecular
test results in this case: (1) the patient is mosaic for the
c.2046dupG variant throughout the body, but at a low
level which was undetected in non-renal tissues, and
the “second hit” in the AML was undetected, or (2) the
patient has a germline variant which remains undetected
with NGS, and the c.2046dupG variant is a somatic mutation present only in the sampled AML.
Since there was low-level mosaicism in tumour tissue
but widespread clinical manifestation of TSC, we propose
that the second explanation is more likely. There are however a number of limitations of using NGS methods which
should be highlighted:
Firstly, minor sequence variants due to somatic mosaicism and sequence variants present in less than 50% of
the patient’s nucleated cells may also go undetected. We
attempted to overcome this issue by performing analysis
in a variety of cell-types.
Secondly, NGS may miss variants within runs of
mononucleotide repeats (e.g., (A)n or (T)n with n > 8 in
the reference sequence). These regions tend to be difficult
to analyse because of strand slippage during amplification and therefore could be overlooked. Importantly,
splice site mutations located more than 20 nucleotides
away from the exon-intron boundary may be undetected.
This is important since deep intronic variants can be detected in up to 40% of the patients with TSC [Tyburczy et
al., 2015a]. Although not available in this case, future
studies using whole-genome sequencing may detect additional variants within deep intronic sites, located greater than 20 nucleotides away from the exon-intron boundary.
Finally, NGS and Sanger sequencing often do not capture or amplify certain regions of the genome due to a
deletion or insertion. For this reason, additional testing
via MLPA was performed for the detection of CNVs,
which was also negative.
Pre-implantation genetic diagnosis (PGD) is increasingly being used as a method to prevent transmission of
genetic diseases in at-risk couples [Brezina and Kutteh,
2015]. However, PGD is only possible if the causative mutation has previously been identified in the family. When
a prospective parent has a germline pathogenic variant,
the chance of passing on the mutation is 50%. If there has
been a post-zygotic mutation causing TSC in the prospective parent, the level of mosaicism can vary from tissue to
tissue, and recurrence risk depends on the percentage of
gonadal cells harbouring the mutation [Naja et al., 2016].
In males, it is sometimes possible to detect gonadal mosaicism through sperm analysis [Giannikou et al., 2019].

In this patient, if PGD were performed and the
c.2046dupG were to be identified in an embryo, a diagnosis of TSC could be confidently made. However, since the
variant likely represents the “second hit”, isolated to the
AML which was sampled, the probability of finding that
variant at the time of PGD would be extremely low. If the
c.2046dupG were absent at PGD, the possibility of TSC
could not be ruled out, and might be as high as 50% if
there is an undetected germline mutation. The same situation would apply to prenatal diagnosis with chorionic
villus sampling or amniocentesis. The patient was counselled that PGD would be an expensive and unreliable
option to achieve her goal of having an unaffected child.
Egg donation would be the only option to ensure that any
TSC variants present in this patient would not be passed
on to any offspring.
This case outlines the challenges of providing genetic
counselling with regards to utility of pre-implantation or
prenatal diagnosis. Caution should be taken when counselling patients with no mutation identified and somatic
mosaicism isolated to one tissue regarding their reproductive risks.
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